arrow
A

Antonino Neri

azienda usl-irccs di reggio emilia
H指数:81
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Latent Epstein–Barr Virus Infection Correlates with Glycosphingolipid Enrichment and Morphological Remodeling of Extracellular Particles

潜伏性EB病毒感染与外泌体糖基鞘脂富集及形态重塑相关

2026-08-300
OA
Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers

多发性骨髓瘤来源外泌体的蛋白质组分析以发现新型骨髓瘤相关生物标志物

2026-08-180
OAAI
Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions

NK和肿瘤细胞状态在多发性骨髓瘤进展中的协同进化,从前体条件开始

2026-05-220
OA
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

MDM2驱动蛋白酶体抑制剂耐药性,并在多发性骨髓瘤中代表一种TP53非依赖性的治疗易损性

Cells
IF5.2
2026-05-010
OA
From Axillary Lymph Node Dissection to Sentinel Node Biopsy in Breast Cancer: A 23-Year Population-Based Large-Sample Study with Long-Term Survival Outcomes

从腋窝淋巴结清扫到前哨淋巴结活检在乳腺癌中的应用:一项为期23年的基于人群的大样本研究及长期生存结果

2026-04-170
OAAI
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort

慢性淋巴细胞白血病的免疫遗传学架构:来自O-CLL1队列的见解

2026-04-070
OAAI
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune Dysfunction

FcγRIIIA基因型在浆细胞恶性疾病中与临床进展、骨病变扩展和免疫功能紊乱相关

Cancers
IF4.4
2026-04-030
OAAI
To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy

治疗还是不治疗:靶向治疗时代早期慢性淋巴细胞白血病的治疗选择

2026-01-010
OAAI
Complications and length of stay after enhanced recovery after surgery compared to conventional care in colorectal cancer patients in Northern Italy

与常规护理相比,加速康复外科后并发症及住院时间的比较(针对意大利北部结直肠癌患者)

2025-12-110
OAAI
Advancing Prognostic Accuracy Beyond Classical N Staging in Colorectal Cancer: An Observational Cohort Study to Define a Lymph Node Ratio Based Risk Score

推进结直肠癌预后准确性超越经典N分期:一项基于队列观察研究,旨在定义一种基于淋巴结比例的风险评分

2025-11-150
OAAI
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma

Cantafio, M.E.G.; Valentino, I.; Torcasio, R.; Ganino, L.; Veneziano, C.; Murfone, P.; Mesuraca, M.; Perrotta, I.; Tallarigo, F.; Agosti, V.; 等. 线粒体分裂因子驱动多发性骨髓瘤中可操作性的代谢脆弱性。Haematologica, 2025; early view. [Google Scholar] [CrossRef]

2025-10-013
OAAI
Impact of COVID-19 on the Stage and Treatment of Endometrial Cancer: A Cancer Registry Analysis from an Italian Comprehensive Cancer Center

COVID-19对子宫内膜癌分期和治疗的影响:一项来自意大利综合癌症中心的癌症登记分析

2025-08-200
PRE
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study
2025-03-010
PRE
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

伊沙图昔单抗、泊马度胺和地塞米松 (IsaPd) 在达雷妥尤单抗难治性多发性骨髓瘤患者中的疗效和预后指标: 一项多中心真实世界研究

2025-02-030
OAAI